Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2011 1
2012 2
2013 1
2014 3
2015 6
2016 8
2017 3
2018 5
2019 2
2020 4
2021 11
2022 11
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib.
Wu JJ, Tseng JS, Zheng ZR, Chu CH, Chen KC, Lin MW, Huang YH, Hsu KH, Yang TY, Yu SL, Chen JS, Ho CC, Chang GC. Wu JJ, et al. Among authors: tseng js. Ther Adv Med Oncol. 2024 Jan 3;16:17588359231220606. doi: 10.1177/17588359231220606. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38188463 Free PMC article.
Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer.
Wang CL, Hsu KH, Chang YH, Ho CC, Chiang CJ, Chen KC, Cheung YC, Huang PC, Chen YR, Chen CY, Hsu CP, Hsia JY, Chen HY, Yang SY, Li YJ, Yang TY, Tseng JS, Chuang CY, Hsiung CA, Chen YM, Huang MS, Yu CJ, Chen KY, Su WC, Chen JJW, Yu SL, Chen CJ, Yang PC, Tsai YH, Chang GC. Wang CL, et al. Among authors: tseng js. J Thorac Oncol. 2023 Nov;18(11):1492-1503. doi: 10.1016/j.jtho.2023.06.018. Epub 2023 Jul 5. J Thorac Oncol. 2023. PMID: 37414358 Free article.
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
Huang YH, Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Chang GC. Huang YH, et al. Among authors: tseng js. Target Oncol. 2023 Jan;18(1):179-180. doi: 10.1007/s11523-022-00928-4. Target Oncol. 2023. PMID: 36334173 Free PMC article. No abstract available.
58 results